BiotechTube

Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/Carboplatin

Phase 3Completed
2 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NSCLC

Conditions

NSCLC

Trial Timeline

Nov 28, 2016 → Nov 12, 2019

NCT ID
NCT02954172

About Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/Carboplatin

Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/Carboplatin is a phase 3 stage product being developed by WuXi Biologics for NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT02954172. Target conditions include NSCLC.

What happened to similar drugs?

7 of 20 similar drugs in NSCLC were approved

Approved (7) Terminated (3) Active (11)
✅DurvalumabAstraZenecaApproved
✅OsimertinibAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Gefitinib + PlaceboAstraZenecaApproved
✅CrizotinibPfizerApproved
✅crizotinibPfizerApproved
✅NivolumabBristol Myers SquibbApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02954172Phase 3Completed

Competing Products

20 competing products in NSCLC

See all competitors
ProductCompanyStageHype Score
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
BBP-398 + osimertinibLianBioPhase 1
11
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)BioAtlaPhase 1/2
26
YH42946YuhanPhase 1/2
39
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + OsimertinibDaiichi SankyoPhase 1
33
U3-1287 + Erlotinib + PlaceboDaiichi SankyoPhase 1/2
32
DS-1205c + OsimertinibDaiichi SankyoPhase 1
21
Datopotamab deruxtecan (Dato-DXd) + DocetaxelDaiichi SankyoPhase 3
47
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789Daiichi SankyoPhase 1
33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + CisplatinDaiichi SankyoPhase 1
33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)Daiichi SankyoPhase 1
33
CS-7017 + erlotinibDaiichi SankyoPhase 2
35
gilteritinibAstellas PharmaPhase 1
36
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
35
naquotinib + midazolamAstellas PharmaPhase 1
29
OSI-906 + Erlotinib + PlaceboAstellas PharmaPhase 2
35
ExisulindAstellas PharmaPhase 1/2
32
naquotinibAstellas PharmaPhase 1
21
ASP8273Astellas PharmaPhase 2
27
TarcevaAstellas PharmaPhase 1
29